AAREYDRUGS94.99

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹270 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations395.6473.9472.3414.7
Other Income7.09.86.16.3
Total Income402.6483.8478.4420.9
Expenses
+ Cost of Materials Consumed387.8472.9450.6401.0
+ Changes in Inventories-5.9-10.83.9-2.1
+ Employee Benefit Expense0.70.80.80.8
+ Finance Costs4.44.05.05.6
+ Depreciation & Amortisation1.71.92.93.2
+ Other Expenses8.58.89.88.3
Total Expenses397.2477.7473.0416.7
EBITDA4.52.37.26.8
EBIT2.80.34.33.6
Profit
PBT before Exceptional Items5.36.15.44.2
Pretax Income5.36.15.44.2
+ Current Tax1.31.41.6-0.0
+ Deferred Tax-0.70.7-0.1-0.7
Tax Expense0.72.11.4-0.7
Net Income4.74.04.04.9
+ Net Income — Continuing Ops4.74.04.04.9
Total Comprehensive Income4.74.04.04.9
Per Share
Basic EPS1.843.271.391.83
Diluted EPS1.843.681.391.83
Per Share — as-filed variants
Basic EPS — Continuing Operations1.841.841.391.47
Diluted EPS — Continuing Operations1.841.841.391.47
Basic EPS — Discontinued Operations0.001.430.000.36
Diluted EPS — Discontinued Operations0.001.840.000.36
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit13.711.917.815.9
Gross Margin %3.472.513.763.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)5.36.15.44.2
Net Income Adj (tax-effected)4.74.04.04.9
EPS Adj1.843.271.391.83
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital2,80,543.02,80,540.328.528.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.